Coloplast remains a leader in intimate healthcare with strong growth, innovation, and dividend support, despite recent weakness. See why CLPBY stock is a buy.

Coloplast has agreed to buy Iceland-based Kerecis, a biologic wound care firm that uses fish skin to develop tissue-transplant products, for up to $1.3 billion, the Danish medical equipment maker ...

Coloplast A/S is acquiring Kerecis hf, a closely held Icelandic maker of fish-skin dressings to treat human wounds, for an enterprise value of up to $1.3 billion.

Coloplast has offered up 8.9 billion Danish kroner, or around $1.3 billion, in the deal. The vast majority—8.2 billion kroner ($1.2 billion)—will be doled out as an upfront cash payment.

Coloplast announced it will acquire wound care product company Kerecis for $1.3 billion. The acquisition will give Coloplast an opportunity to “strategically strengthen [its] presence in the advanced ...

Coloplast exercised some of this flexibility in fiscal 2022 as it acquired Atos Medical, bumping net debt/EBITDA up to 2.3 times.

Coloplast's woundcare portfolio is relatively limited, especially when compared with the breadth of products from Smith & Nephew, and Convatec, which include high-tech solutions such as negative ...